Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.05%
#3 Meteora Meteora +11.24%
#4 Glidr Glidr +9.59%
#5 Unit Pump Unit Pump +8.98%
#6 OPENLOOT OPENLOOT +8.94%
#7 Pump.fun Pump.fun +8.52%
#8 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.55%
#9 eCash eCash +7.18%
#10 Bitway Bitway +6.51%
Coin of the day
PulseChain PulseChain
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Pozycja w akcjach #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Cena akcji
$0.55
Ostatnia synchronizacja: 2025-02-11
Kapitalizacja rynkowa
$28.90M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Kategoria

Healthcare
Historia stopy dywidendy dla Marinus Pharmaceuticals, Inc. (MRNS)
Stopa dywidendy (TTM) dla Marinus Pharmaceuticals, Inc. (symbol akcji: MRNS) na dzień 2022-12-31 wynosi: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Marinus Pharmaceuticals, Inc. (MRNS) od 2012 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH